EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access

Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?

Dariusz A Hareza, Sara E Cosgrove, Patricia J Simner, Anthony D Harris, Yehudit Bergman, Rick Conzemius, Emily Jacobs, Stephan Beisken, Pranita D Tamma iD

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad703 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Dariusz A Hareza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: beta-Lactamases, Anti-Bacterial Agents, Enterobacteriaceae Infections, Microbial Sensitivity Tests. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCEZID CDC HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Investigations into antibiotics for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infections (BSIs) have focused on blaCTX-M genes. Patient outcomes from non–CTX-M-producing ESBL-E BSIs and optimal treatment are unknown.

Methods

A multicenter observational study investigating 500 consecutive patients with ceftriaxone-resistant Enterobacterales BSIs during 2018–2022 was conducted. Broth microdilution and whole-genome sequencing confirmed antibiotic susceptibilities and ESBL gene presence, respectively. Inverse probability weighting (IPW) using propensity scores ensured patients with non–CTX-M and CTX-M ESBL-E BSIs were similar before outcome evaluation.

Results

396 patients (79.2%) were confirmed to have an ESBL-E BSI. ESBL gene family prevalence was as follows: blaCTX-M (n = 370), blaSHV (n = 16), blaOXY (n = 12), and blaVEB (n = 5). ESBL gene identification was not limited to Escherichia coli and Klebsiella species. In the IPW cohort, there was no difference in 30-day mortality or ESBL-E infection recurrence between the non–CTX-M and CTX-M groups (odds ratio [OR], 0.99; 95% confidence interval [CI], .87–1.11; P = .83 and OR, 1.10; 95% CI, .85–1.42; P = .47, respectively). In an exploratory analysis limited to the non–CTX-M group, 86% of the 21 patients who received meropenem were alive on day 30; none of the 5 patients who received piperacillin-tazobactam were alive on day 30.

Conclusions

Our findings suggest that non–CTX-M and CTX-M ESBL-E BSIs are equally concerning and associated with similar clinical outcomes. Meropenem may be associated with improved survival in patients with non–CTX-M ESBL-E BSIs, underscoring the potential benefit of comprehensive molecular diagnostics to enable early antibiotic optimization for ESBL-E BSIs beyond just blaCTX-M genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamasesAnti-Bacterial AgentsEnterobacteriaceae InfectionsMicrobial Sensitivity TestsCarbapenemsBacteremiaHumansMaleFemaleAgedMiddle AgedWhole Genome SequencingEnterobacteriaceaeAged, 80 and over

Stichwörter der Autor:innen

CTX-MESBLsSHVantimicrobial resistancepiperacillin-tazobactam

Substanzen

beta-LactamasesAnti-Bacterial AgentsCarbapenems

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Ares Genetics, Vienna, Austria.
  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Pranita D Tamma

Förderung

  • NIAID NIH HHS
  • NCEZID CDC HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Hareza, D. A., Cosgrove, S. E., Simner, P. J., Harris, A. D., Bergman, Y., Conzemius, R., Jacobs, E., Beisken, S., & Tamma, P. D. (2024). Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad703

Vancouver

Hareza DA, Cosgrove SE, Simner PJ, Harris AD, Bergman Y, Conzemius R, et al. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad703

BibTeX
@article{Hareza2024,
  author = {Hareza, Dariusz A and Cosgrove, Sara E and Simner, Patricia J and Harris, Anthony D and Bergman, Yehudit and Conzemius, Rick and Jacobs, Emily and Beisken, Stephan and Tamma, Pranita D},
  title = {Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad703}
}
Kostenlos starten →